Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.25 +0.7%	$2.79	$1.89 ▼ $4.33	$1.26B	0.62	3.47 million shs	4.25 million shs
BGM BGM Group	$9.66 -1.9%	$12.39	$5.26 ▼ $17.17	$957.64M	1.29	34,061 shs	30,395 shs
PAHC Phibro Animal Health	$31.14 -0.8%	$24.31	$16.16 ▼ $31.80	$1.27B	0.75	219,757 shs	382,115 shs
RCKT Rocket Pharmaceuticals	$3.16 -1.3%	$4.15	$2.19 ▼ $26.98	$341.71M	0.67	2.24 million shs	2.50 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+0.71%	+11.70%	+40.73%	+77.08%	+51.79%
BGM BGM Group	-1.93%	-5.39%	-40.95%	-3.50%	+965,999,900.00%
PAHC Phibro Animal Health	-0.80%	+11.25%	+27.94%	+77.94%	+89.99%
RCKT Rocket Pharmaceuticals	-1.25%	+9.12%	0.00%	-40.04%	-85.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.5951 of 5 stars	3.5	1.0	0.0	0.0	3.1	3.3	0.0
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	3.738 of 5 stars	0.9	2.0	2.5	1.1	3.0	3.3	2.5
RCKT Rocket Pharmaceuticals	4.8888 of 5 stars	4.2	2.0	0.0	4.7	2.3	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$7.50	76.47% Upside
BGM BGM Group	0.00	N/A	N/A	N/A
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-21.64% Downside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	488.61% Upside

Current Analyst Ratings Breakdown

Latest RCKT, PAHC, BGM, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	ABCL AbCellera Biologics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	ABCL AbCellera Biologics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	43.99	N/A	N/A	$3.58 per share	1.19
BGM BGM Group	$25.10M	37.42	N/A	N/A	$7.34 per share	1.32
PAHC Phibro Animal Health	$1.02B	1.24	$2.10 per share	14.85	$6.34 per share	4.91
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/7/2025 (Estimated)
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$2.42M	$0.78	39.92	14.83	0.53	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)

Latest RCKT, PAHC, BGM, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	N/A	N/A	N/A	$7.55 million	N/A
8/4/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	N/A	N/A	N/A	$4.36 million	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.54%	N/A	61.54%	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest RCKT, PAHC, BGM, and ABCL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
BGM BGM Group	N/A	N/A	N/A
PAHC Phibro Animal Health	2.67	2.91	1.23
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
BGM BGM Group	N/A
PAHC Phibro Animal Health	99.34%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
BGM BGM Group	58.66%
PAHC Phibro Animal Health	50.07%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable

RCKT, PAHC, BGM, and ABCL Headlines

Recent News About These Companies

The Gross Law Firm Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 – RCKT

July 10 at 4:52 PM | globenewswire.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

July 10 at 4:16 PM | globenewswire.com

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 10 at 4:00 PM | globenewswire.com

Contact The Gross Law Firm by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc.(RCKT)

July 10 at 9:00 AM | prnewswire.com

Not Rocket Science Launches Game Changing RTD Shake with 26g Protein for Daily Life

July 10 at 8:11 AM | english.newsnationtv.comE

NUST Rocket Team Wins “Most Dedicated Team” at UK’s Mach-25 Competition

July 10 at 3:10 AM | techjuice.pkT

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT - Stockhouse

July 9 at 10:09 PM | stockhouse.com

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

July 9 at 5:16 PM | prnewswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman

July 9 at 5:11 PM | globenewswire.com

Rocket Announce Debut Album, Hear: “Wide Awake”

July 9 at 5:08 PM | pastemagazine.comP

Rocket CRM Announces Advanced CRM Automation System to Streamline Customer Management and Operational Efficiency

July 9 at 5:08 PM | freep.comF

2025-07-07 | Rocket Pharmaceuticals, Inc. (RCKT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 11, 2025 | NDAQ:RCKT | Press Release - Stockhouse

July 8 at 8:33 PM | stockhouse.com

Rocket Pharmaceuticals, Inc. (RCKT) - Yahoo Finance

July 8 at 8:33 PM | finance.yahoo.com

Levi & Korsinsky Notifies Shareholders of Rocket Pharmaceuticals, Inc.(RCKT) of a Class Action Lawsuit and an Upcoming Deadline

July 8 at 3:49 PM | globenewswire.com

India Bolsters Naval Might with Extended Range Anti-Submarine Rocket Success

July 8 at 3:31 PM | devdiscourse.comD

India Boosts Naval Strength with Indigenous Anti-Submarine Rocket Success

July 8 at 3:31 PM | devdiscourse.comD

Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

July 8 at 12:00 PM | prnewswire.com

RCKT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RCKT To Contact Him Directly To Discuss Their Options

July 8 at 11:20 AM | prnewswire.com

Robbins Geller Rudman & Dowd LLP Files Rocket Pharmaceuticals Class Action Lawsuit

July 8 at 10:31 AM | lawyer-monthly.comL

August 11, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RCKT

July 8 at 9:00 AM | prnewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Share Price Passes Below 50 Day Moving Average - Should You Sell?

July 8 at 4:56 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT, PAHC, BGM, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.25 +0.03 (+0.71%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$4.30 +0.05 (+1.18%)

As of 07/10/2025 07:58 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

BGM Group NASDAQ:BGM

$9.66 -0.19 (-1.93%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$9.64 -0.03 (-0.26%)

As of 07/10/2025 05:57 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Phibro Animal Health NASDAQ:PAHC

$31.14 -0.25 (-0.80%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$31.16 +0.02 (+0.05%)

As of 07/10/2025 04:06 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.16 -0.04 (-1.25%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$3.16 0.00 (0.00%)

As of 07/10/2025 07:39 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time